Spero Therapeutics announced on April 28, 2025, that Esther Rajavelu would serve as its permanent President and Chief Executive Officer, effective May 2, 2025. Ms. Rajavelu had previously served as Interim President and CEO since January 2025.
She will continue to hold the roles of Chief Financial Officer and Treasurer, positions she has held since November 2023. This appointment follows the mutual agreement for separation with former President and CEO Sath Shukla, who also stepped down from the Board of Directors.
The company highlighted Ms. Rajavelu's focus on advancing Spero’s programs and strengthening its partnership with GSK. Spero is preparing for an update on its PIVOT-PO Phase 3 trial for tebipenem HBr in the current quarter, which remains the company's highest priority.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.